INTRODUCTION. Ireland

Size: px
Start display at page:

Download "INTRODUCTION. Ireland"

Transcription

1 Microbiology (215), 161, DOI 1.199/mic Streptozotocin-induced type-1-diabetes disease onset in Sprague Dawley rats is associated with an altered intestinal microbiota composition and decreased diversity Elaine Patterson, 1,2,3 Tatiana M. Marques, 1,2,3 Orla O Sullivan, 1,2 Patrick Fitzgerald, 1 Gerald F. Fitzgerald, 1,3 Paul D. Cotter, 1,2 Timothy G. Dinan, 1 John F. Cryan, 1 Catherine Stanton 1,2 and R. Paul Ross 1,2 Correspondence R. Paul Ross paul.ross@teagasc.ie 1 Alimentary Pharmabiotic Centre, Biosciences Institute, University College Cork, Co. Cork, Ireland 2 Teagasc Food Research Centre, Food Biosciences Department, Moorepark, Fermoy, Co. Cork, Ireland 3 Department of Microbiology, University College Cork, Co. Cork, Ireland Received 18 July 214 Accepted 31 October 214 There is a growing appreciation that microbiota composition can significantly affect host health and play a role in disease onset and progression. This study assessed the impact of streptozotocin (STZ)-induced type-1-diabetes (T1D) on intestinal microbiota composition and diversity in Sprague Dawley rats, compared with healthy controls over time. T1D was induced by injection of a single dose (6 mg STZ kg 1 ) of STZ, administered via the intraperitoneal cavity. Total DNA was isolated from faecal pellets at weeks (pre-stz injection), 1, 2 and 4 and from caecal content at week 5 from both healthy and T1D groups. High-throughput 16S rrna sequencing was employed to investigate intestinal microbiota composition. The data revealed that although intestinal microbiota composition between the groups was similar at week, a dramatic impact of T1D development on the microbiota was apparent post-stz injection and for up to 5 weeks. Most notably, T1D onset was associated with a shift in the Bacteroidetes : Firmicutes ratio (P,.5), while at the genus level, increased proportions of lactic acid producing bacteria such as Lactobacillus and Bifidobacterium were associated with the later stages of T1D progression (P,.5). Coincidently, T1D increased caecal lactate levels (P,.5). Microbial diversity was also reduced following T1D (P,.5). Principle co-ordinate analyses demonstrated temporal clustering in T1D and control groups with distinct separation between groups. The results provide a comprehensive account of how T1D is associated with an altered intestinal microbiota composition and reduced microbial diversity over time. INTRODUCTION Type-1-diabetes (T1D) is an organ-specific autoimmune disease involving the selective destruction of insulin-producing pancreatic b-cells. While the pathophysiology of T1D is not yet entirely clear, it is the genetic predisposition of an individual combined with environmental factors which initiate an autoimmune response (Boerner & Sarvetnick, 211). Genetically, the human leukocyte antigen (HLA) complex is the strongest predictor of T1D risk, whereby after Abbreviations: HLA, human leukocyte antigen; OTU, operational taxonomical unit; SCFA, short-chain fatty acid; STZ, streptozotocin; T1D, type-1-diabetes. Five supplementary figures and three supplementary tables are available with the online Supplementary Material. HLA, the strongest susceptibility locus is in the insulin gene itself (Noble & Erlich, 212). Over time, genetic susceptibility activates both the innate and adaptive immune systems but remains subclinical, until approximately 8 % of the b-cell mass is destroyed (Notkins & Lernmark, 21). Over time, b-cell destruction results in insulin deficiency, worsening hyperglycemia and an eventual call for insulin therapy. As the incidence of T1D is increasing at a rate far beyond the rate of population growth, additional emphasis has been placed on the contribution of environmental factors towards disease onset (Ehehalt et al., 21; Patterson et al., 21; Vaarala et al., 28). Indeed, the intestinal microbiota is an environmental factor that cannot be overlooked as a contributor towards T1D development or a factor that is significantly altered as a result of T1D development G 215 The Authors Printed in Great Britain

2 Impact of STZ-induced T1D on microbiota composition Many studies have linked alterations in the intestinal microbiota composition with conditions such as obesity (Ley et al., 26, 25; Murphy et al., 21; Turnbaugh et al., 26), inflammatory bowel disease (Greenblum et al., 212), colitis (Bellavia et al., 213; Klimesova et al., 213) and T1D (Giongo et al., 211; Murri et al., 213; Roesch et al., 29). Moreover, risk of T1D onset in childhood is higher in children delivered by Caesarean section (Cardwell et al., 28), where there is also altered microbiota composition (Dominguez-Bello et al., 21). Previous studies have examined the role of the intestinal microbiota in the development of T1D but these are often limited due to the models used [i.e. genetically pre-disposed animals (Roesch et al., 29) and humans (Brown et al., 211; de Goffau et al., 213; Giongo et al., 211; Murri et al., 213) who develop T1D, with conflicting results. Oral administration of the probiotic compound VSL#3 to non-obese diabetic mice prevented spontaneous T1D development (Calcinaro et al., 25), while antibiotics have also been shown to prevent autoimmune diabetes in bio-breeding diabetesprone rats (Brugman et al., 26). Thus, the intestinal microbiota have demonstrated a capacity to influence diabetes and become altered due to disease development (Atkinson & Chervonsky, 212; King & Sarvetnick, 211). Originally derived from cultures of Streptomyces achromogenes, streptozotocin (STZ) has been clinically used as a chemotherapeutic agent in the treatment of pancreatic b-cell carcinoma (Lenzen, 28). STZ produces rapid pancreatic b-cell destruction, resulting in hypoinsulinemia and hyperglycemia. The selectivity for b-cells is associated with preferential accumulation of the chemical in these cells after entry through glucose transporter 2, whereby chemical structural similarity with glucose allows STZ to bind to this receptor. It is currently unclear what the direct effect of STZ induced T1D development and progression is on the intestinal microbiota composition of the host. To this end, in this study, diabetes was induced in male Sprague Dawley rats through a single intraperitoneal injection of STZ. The impact of T1D disease onset and progression on intestinal microbiota composition and microbial fermentation products was investigated. DNA was isolated from faecal pellets at weeks, (pre-stz injection in one of the groups), 1, 2 and 4, and from caecal content at week 5 from T1D and healthy control rats and prepared for 16S rrna pyrosequencing. METHODS Assessment of antimicrobial activity of STZ. Given the microbial origin of STZ, it was important to first assess its own antimicrobial activity. Bioactivity of STZ (Sigma) was assessed by well-diffusion assays. For this purpose, molten agar was cooled to 48 uc and seeded with fresh overnight cultures of various Gram-positive (Bifidobacterium, Lactobacillus and Listeria) and Gram-negative (Escherichia coli and Cronobacter) bacterial strains. Twenty millilitres of inoculated medium was dispensed into sterile Petri dishes, allowed to solidify and dried. Wells (4.6 mm in diameter) were then bored in the seeded agar plates and 5 ml volumes of various concentrations (7.5, 4, 2 and 1 mg STZ ml 21 ) of freshly prepared STZ in filter-sterilized sodium citrate buffer (5 mm, ph 4.5) to be assayed were dispensed into the wells. Petri dishes were incubated accordingly for each of the strains used. Animals and treatment. Male Sprague Dawley rats were purchased (Harlan Laboratories) at 5 weeks of age and housed under barriermaintained conditions within the Biological Services unit, University College Cork (UCC). Rats were allowed to acclimatise for 1 week before the start of the study and were fed ad libitum with Teklad Global Standard Rodent Diet (#218S; Harlan Laboratories) with free access to water at all times. Rats were housed in groups of five per cage and kept in a controlled environment at 25 uc under a 12 h light/12 h dark cycle. The rats were divided into two groups: a nondiabetic healthy control group and an STZ-induced T1D group. After 1 week of acclimatization, T1D was induced in the latter group by injection of a single dose (6 mg STZ kg 21 ) of freshly prepared STZ (Sigma) administered via the intraperitoneal cavity, according to a previously described method (Wu & Huan, 28). Glucose levels were measured in triplicate using a Contour Next glucometer (Bayer) in blood samples collected from a tail vein each week. Rats with blood glucose higher than 2 mg glucose dl 21 were considered diabetic and STZ induced rats with lower glucose levels were excluded from the rest of the study (n51 rats per group). Body weight was assessed and fresh faecal pellets were collected weekly. After 5 weeks, the rats were killed by decapitation. Caecal content was removed from individual rats and flash-frozen immediately on dry ice. All samples were stored at 28 uc until processed. All experiments were conducted in accordance with the European Directive 86/69/EEC, the Recommendation 27/526/65/EC, and approved by the Animal Experimentation Ethics Committee of UCC. All efforts were made to minimize animal suffering and to reduce the number of animals used. DNA isolation from faecal pellets and caecal content and highthroughput amplicon sequencing. Total DNA was isolated from fresh individual rat faecal pellets collected at weeks (pre-stzinduced diabetes in the T1D group), 1, 2 and 4 post-stz injection and from the individual caecal content of all rats, 5 weeks following STZ injection using the QIAmp DNA Stool Mini kit (Qiagen) (n51 per group). Furthermore, total DNA was extracted from faecal pellets at weeks, 1, 2 and 4, and from caecal content at week 5 from rats which were injected with STZ but that did not develop T1D to assess the antimicrobial activity of STZ (n52). DNA extraction was coupled with an initial bead-beating step (three times, 3 s). Isolated DNA was then stored at 22 uc until further processing. The microbiota composition of the samples was established by amplicon sequencing; universal 16S rrna primers estimated to bind to 94.6 % of all 16S genes, flanking the V4 region [i.e. the forward primer F1 (59-AYT- GGGYDTAAAGNG-39) and a combination of four reverse primers: R1 (59-TACCRGGGTHTCTAATCC-39), R2 (59-TACCAGAGTATC- TAATTC-39), R3 (59-CTACDSRGGTMTCTAATC-39) and R4 (59- TACNVGGGTATCTAATC) (Ribosomal Database Project s Pyrosequencing Pipeline: were employed for PCR amplification. Molecular identifier tags were attached between the 454 adaptor sequence and the target-specific primer sequence, allowing for identification of individual sequences from the pooled amplicons. Ampure purification system (Beckman Coulter) was used to clean the amplicons prior to being sequenced on a 454 Genome Sequencer FLX platform (Roche Diagnostics), in line with 454 protocols at the Teagasc high-throughput sequencing centre. Bioinformatics sequence analysis. Quality trimming of sequence reads was performed using the Qiime suite of tools (version 1.7) (Caporaso et al., 21); reads shorter than 2 bp, reads that failed to reach a quality score of 25 and those that were not exact matches to barcoded tags and primer sequence were discarded. A locally installed version of SILVA 16S rrna database (version 16) (Pruesse et al., 27) was used to BLAST (Altschul et al., 1997) the trimmed sequence 183

3 E. Patterson and others using default parameters. Resulting BLAST output files were parsed through MEGAN (Huson et al., 27); similar to previous studies a bitscore cut-off of 86 was selected (Rea et al., 211; Urich et al., 28). Clustering of sequence reads into operational taxonomical units (OTUs) at 97 % identity and subsequent alignments were achieved using QIIME suite software tools (Caporaso et al., 21). ChimeraSlayer was used to remove chimeric OTUs from aligned OTUs and the FastTreeMP tool reconstructed a phylogenetic tree (Haas et al., 211; Price et al., 21). Alpha and beta diversities were calculated on the sequence reads. Principal co-ordinate analyses were performed on the samples and viewed within KiNG viewer (Chen et al., 29). Short-chain fatty acid (SCFA), lactic and formic acid analysis of caecal content. SCFA analysis was performed as previously described (Wall et al., 212). Briefly, caecal content was vortexmixed with MilliQ water, incubated at room temperature for 1 min and centrifuged to pellet bacteria and other solids. The supernatant was filtered, transferred to a clear GC vial and 2-ethylbutyric acid (Sigma) was added as internal standard. The concentrations of SCFA were measured using a Varian 38 GC flame-ionization system, fitted with a ZB-FFAP column (3 m6.32 mm6.25 mm; Phenomenex). The initial oven temperature was set at 1 uc for.5 min, raised to 18 uc at8uc min 21 and held for 1 min, then increased to 2 uc at 2 uc min 21, and finally held at 2 uc for 5 min. The temperature of the injector and the detector were set at 24 uc and 25 uc, respectively. Helium was used as the carrier gas at a flow rate of 1.3 ml min 21. A standard curve was built with different concentrations of a standard mix containing acetic acid, propionic acid, n-butyric acid and iso-butyric acid (Sigma). Peaks were integrated by using the Varian Star Chromatography Workstation, version 6. software. Formic acid and lactic acid were measured using formic acid and DL-lactate commercial kits (Megazyme). Statistical analysis. All results are presented as means±sem (per group). To assess whether differences between treatment groups were significant, the unpaired Student s t-test was used with the use of GraphPad Prism version 6. for Windows (GraphPad Software). Statistical significance was accepted at P,.5. Compositional data were statistically analysed using the non-parametric Mann Whitney and Kruskal Wallis tests (Kruskal & Wallis, 1952) to estimate the relationships between different groups using GraphPad Prism version 6.. Statistical significance was accepted at P,.5. RESULTS Antimicrobial activity of STZ Initially, the antimicrobial activity of different concentrations of STZ was tested against Gram-positive (Bifidobacterium, Lactobacillus and Listeria) and Gram-negative (E. coli and Cronobacter) bacterial strains. At a concentration of 7.5 mg STZ ml 21, STZ produced a clear zone of inhibition of strains Lactobacillus bulgaricus, Lactobacillus plantarum, Lactobacillus gasseri and Bifidobacterium infantis which decreased at concentrations of 4, 2 and 1 mg STZ ml 21 (data not shown). A concentration of 7.5 mg STZ ml 21 had a bacteriostatic effect on Bifidobacterium breve, Lactobacillus acidophilus, E. coli and Cronobacter sakazakii, which decreased at concentrations of 4, 2 and 1 mg STZ ml 21 (data not shown). No zone of inhibition was observed for any concentration of STZ on Bifidobacterium bifidus and Listeria monocytogenes (data not shown). Induction of T1D by STZ injection in rats One week after STZ injection, rats were severely diabetic as indicated by elevated blood glucose levels (572.6±1.3 mg glucose dl 21 ), compared with the normoglycemic range observed in healthy controls (14.2±2.1 mg glucose dl 21 ) (P,.5; Fig. 1a). The chronic increases in blood glucose levels were maintained throughout the study period (Fig. 1a). Diabetic rats exhibited polyuria, polydipsia, hyperphagia and excessive faecal output (data not shown). Diabetic rats displayed significant decreases in percentage body weight gain from week 1 onwards (following STZ injection), compared with healthy controls (P,.5; Fig. 1b). STZ induced T1D decreases a-diversity of the rat intestinal microbiota over time A total of reads were sequenced, corresponding to a total of reads per group and an average of 7857 reads per rat. At the 97 % similarity level, a total of five metrics were used to estimate a-diversity; Shannon index Simpson index, Chao1 richness estimation (Figs. S1 S3, available in the online Supplementary Material), phylogenetic diversity and observed species (Fig. 2). At week, pre-stz injection and T1D induction in one of the groups, no differences were observed across any of the five metrics calculated between the groups (Figs 2 and S1 S3). This indicated that all rats in the T1D group had similar levels of diversity pre-stz injection. However, 1, 2, 4 and 5 weeks post-stz injection, Chao1, phylogenetic diversity and observed species were all significantly reduced in the T1D group compared with healthy controls (P,.5; Figs 2 and S1). While Shannon diversity data revealed no change to the biodiversity of the microbiota within the healthy controls and the T1D group at week 2, significant reductions to the diversity profile were found between the T1D group and the healthy controls at all other time points taken (P,.5; Fig. S2a, b). Similarly, the Simpson diversity index-based analysis, which also takes into account the number of species present and the relative abundance of each species, highlighted a significant reduction in diversity in animals induced with T1D at 1, 4 and 5 weeks following STZ injection, compared with healthy controls (P,.5; Fig. S3a, b). Rarefaction curves were seen to be parallel (Fig. S4), indicating that additional sampling would yield a limited increase in species richness. b-diversity highlights an STZ-induced T1D effect on microbial population variation over time as disease progresses Principal co-ordinate analyses, based on unweighted Unifrac distances of the 16S rrna sequences, illustrated changes to the microbial populations following STZinduced T1D, compared with healthy controls. Fig. 3 shows data points corresponding to healthy controls (red) cluster closely together between weeks, 1, 2, 4 and 5 regardless of the time point. Similarly, Fig. 3 also shows 184 Microbiology 161

4 Impact of STZ-induced T1D on microbiota composition (a) Blood glucose levels (mg dl 1 ) STZ Healthy T1D (b) 1 Weight gain (%) STZ Healthy T1D Time (weeks) Time (weeks) Fig. 1. (a) Blood glucose levels of healthy control and T1D rats (n51 per group) and (b) Percentage body weight gain over the eight-week trial. At week 3, T1D was induced in one of the groups by injection of a single dose of STZ, administered via the intra-abdominal cavity. Error bars represent SD. data points corresponding to T1D rats (blue) initially cluster close together with healthy controls (red) at week, since T1D had not been induced at this time point. However, subsequent data points corresponding to the T1D rats (blue), as the trial progressed from week 1 to 5 following T1D induction, became increasingly distant from the healthy control data points (red). Individual data points within particular time points for the T1D group (blue) became much more dispersed and failed to form distinct clusters with each other (Fig. 3). These results are in line with the a-diversity and taxonomical data presented since data points corresponding to T1D rats cluster away from those corresponding to healthy controls in all time points from week 1 onwards (post-stz injection). Furthermore, Fig. S5 shows data points corresponding to the STZ-injected group that did not develop T1D superimposed on the principal co-ordinate analyses plot of Fig. 3. Green data points correspond to this group (n52) over the five time points and highlight that STZ injection did not alter the intestinal microbiota composition after week (data points corresponding to this group cluster well together and do not disperse after STZ injection). Taxonomical analysis highlights the effect of STZinduced T1D on intestinal microbial composition over time Taxonomy based analysis of the assigned sequences highlighted few differences in the intestinal microbiota populations between the groups at week, pre-stz injection. While no significant differences were observed at the phylum level at week (Fig. 4), significantly lower relative proportions of Clostridiaceae (P,.5; Fig. 5) and Clostridium (P,.5; Fig. 6) were found at the family and genus levels, respectively, while the proportions of Parabacteroides were significantly increased in the group yet to be induced with T1D, compared with the control group (P,.5; Fig. 6). Analysis of the microbial profile of the intestine at week 1 (post-stz injection in one of the groups) revealed many statistically-significant differences between the groups at all levels. While the relative abundance of the Tenericutes population was increased in the T1D group (P,.5; Fig. 4), the proportions of Actinobacteria and Deferribacteres were reduced (P,.5; Fig. 4), compared with healthy controls. Most notably, just 1 week after STZ injection, the proportions of Bacteroidetes were increased (P,.5; Fig. 4) in the T1D group, while the Firmicutes population was reduced (P,.5; Fig. 4), compared with healthy controls. At the family level, the proportions of S24-7, Prevotellaceae, Erysipelotrichaceae, Porphyromonadaceae and Anaeroplasmataceae were increased in the T1D group (P,.5; Fig. 5), while Bifidobacteriaceae and Peptococcaceae were reduced, compared with healthy controls (P,.5; Fig. 5). At the genus level, both the proportions of Parabacteroides and Mucispirillium were increased (P,.5; Fig. 6) while the proportions of Ruminococcus were reduced (P,.5; Fig. 6) in the T1D group, compared with healthy controls. While the significant changes in the relative proportions of certain intestinal microbiota populations at week 2 remained the same as week 1, many more changes to the intestinal microbiota were observed at the family and genus levels 2 weeks post-stz-induced T1D, compared with healthy controls. At the phylum level, the proportions of Firmicutes remained lower (P,.5; Fig. 4), while the proportions of Deferribacteres increased (P,.5; Fig. 4) in the T1D group, compared with healthy controls. Similar to week 1, the proportions of Prevotellaceae and Erysipelotrichaceae remained higher while Peptococcaceae remained lower in the T1D group, compared with healthy controls (P,.5; Fig. 5), while the proportions of Porphyromonadaceae shifted from being higher at week 1 to lower in the T1D group at week 2 (P,.5; Fig. 5). Progression of T1D increased the proportions of Lactobacillaceae, Peptostreptococcaceae and Clostridiaceae (P,.5; Fig. 5), while reducing the proportions of RF-9 gut group (P,.5; Fig. 5), after 2 weeks in the T1D group when compared with healthy controls. At the genus level, the proportions of Ruminococcus and Mucispirillium remained lower (P,.5; Fig. 6) and higher (P,.5; Fig. 6), respectively, in the T1D 185

5 E. Patterson and others Week (a) Phylogenetic diversity Week 1 (a) Phylogenetic diversity (b) Observed species 9 Healthy T1D Healthy T1D ** (b) ** Healthy T1D Healthy T1D Observed species Week 2 (a) 6 *** (b) Phylogenetic diversity 3 5 Healthy T1D Healthy T1D Observed species *** Week 4 (a) Phylogenetic diversity (b) *** Observed species 9 *** Healthy T1D Healthy T1D Week 5 (a) 5 Phylogenetic diversity (b) ** 1 ** Observed species Healthy T1D Healthy T1D Fig. 2. Phylogenetic diversity (a) and observed species (b) metrics of a-diversity between healthy control and T1D rats (n51 per group) at weeks, 1, 2, 4 and 5. The non-parametric Mann Whitney test was used to estimate the relationship between the groups. Statistical significance was accepted at P,.5. **P,.1, *** P, Microbiology 161

6 Impact of STZ-induced T1D on microbiota composition PC2 - percent variation explained 3.96% PCoA - PC1 vs PC PC1 - percent variation explained 11.27% Healthy control STZ-induced T1D Fig. 3. Principal co-ordinate analysis (PCoA) based on unweighted UniFrac distances in STZ-induced T1D (blue) and healthy control (red) rats (n51 per group) over the five time points measured. group, similar to week 1, compared with healthy controls. Significant increases in the proportions of Bacteroides, Lactobacillus, Turicibacter and Clostridium were also observed 2 weeks after STZ-induced diabetes (P,.5; Relative abundance versus controls (%) S24-7 Bacteroidaceae Prevotellaceae Bifidobacteriaceae Lactobacillaceae Erysipelotrichaceae Lachnospiraceae Peptostreptococcaceae Ruminococcaceae Alcaligenaceae Porhyromonadaceae Week Week 1 Week 2 Week 4 Peptococcaceae Anaeroplasmataceae RF9 Fig. 5. Family level distributions of the microbial communities either significantly increased or decreased in the faecal content of T1D rats, compared with healthy controls (n51 per group) between weeks, 1, 2 and 4.The non-parametric Mann Whitney test was used to estimate the relationship between the groups. Statistical significance was accepted at P,.5. Vertical bars represent significant increases and decreases in the percentage relative abundances in the microbiota composition in the T1D group versus healthy controls. Clostridiaceae Relative abundance versus controls (%) Bacteroidetes Firmicutes Tenericutes Actinobacteria Proteobacteria Week 1 Week 2 Week 4 Fig. 4. Phylum level distributions of the microbial communities either significantly increased or decreased in the faecal content of T1D rats, compared with healthy controls (n51 per group) between weeks 1, 2 and 4. No significant differences were observed at the phylum level between the groups at week. The non-parametric Mann Whitney test was used to estimate the relationship between the groups. Statistical significance was accepted at P,.5. Vertical bars represent significant increases and decreases in the percentage relative abundances in the microbiota composition in the T1D group versus healthy controls. Deferribacteres Fig. 6), compared with healthy controls. Parabacteroides were reduced 2 weeks after STZ-induced T1D, compared with healthy controls (P,.5; Fig. 6). The proportions of Ruminococcaceae incertae sedis, one of the most dominant populations at the genus level, was reduced at week 2 in the T1D group, compared with healthy controls (P,.5; Fig. 6). Four weeks after STZ-induced T1D, the relative proportions of Tenericutes, Actinobacteria and Proteobacteria were higher in the T1D group (P,.5; Fig. 4), compared with healthy controls. The abundance of Firmicutes remained lower in the T1D group, compared with healthy controls (P,.5; Fig. 4). At the family level, Prevotellaceae recovered in the healthy controls, while Lactobacillaceae and Clostridiaceae remained higher (P,.5; Fig. 5), and Peptococcaceae and RF-9 gut group remained lower in the T1D group, compared with healthy controls (P,.5; Fig. 5). The abundance of Porphyromonadaceae increased in the T1D group, compared with healthy controls (P,.5; Fig. 5). Bacteroidaceae, Bifidobacteriaceae and Alcaligenaceae proportions increased (P,.5; Fig. 5), while Ruminococcaceae and Lachnospiraceae proportions decreased (P,.5; Fig. 5), compared with healthy controls. Correlating with the changes seen at the family level, the abundances of Parasuterella, Bifidobacterium, Lactobacillus and Clostridium were all increased (P,.5; Fig. 6), while the proportions of 187

7 E. Patterson and others Relative abundance versus controls (%) Parasutterella Bacteroides Alistipes Parabacteroides Bifidobacterium Lactobacillus Week Week 1 Week 2 Week 4 Fig. 6. Genus level distributions of the microbial communities either significantly increased or decreased in the faecal content of T1D rats, compared with healthy controls (n51 per group) between weeks, 1, 2 and 4. The non-parametric Mann Whitney test was used to estimate the relationship between the groups. Statistical significance was accepted at P,.5. Vertical bars represent significant increases and decreases in the percentage relative abundances in the microbiota composition in the T1D group versus healthy controls. Turicibacter Ruminococcus Ruminococcaceae incertae sedis Clostridium Mucispirillum Parasuterella, Bifidobacterium, Bacteroides and Phascolarctobacterium were higher (P,.5; Fig. 7c), while the proportions of Alistipes, Ruminococcus, Ruminococcaceae incertae sedis, Peptostreptococcaceae Incertae Sedis and Mucispirillium were lower (P,.5; Fig. 7c) in the T1D group, compared with healthy controls. Throughout the study, from week to 5, the relative populations of the intestinal microbiota at phylum, family and genus levels fluctuated only slightly within the healthy control group (Table S1). In contrast, the proportions of the intestinal microbiota at all levels in the T1D-induced group fluctuated significantly at all weeks following T1D induction (Table S2). Most notably, the relative proportions of Actinobacteria and Proteobacteria were higher (P,.5; Table S2) at the later stages of T1D development, compared with week (pre-stz injection). In addition, while the intestinal microbiota of rats injected with STZ but did not develop T1D fluctuated between the time points taken, changes to the relative abundance did not reflect the same changes observed in the STZ-induced T1D group and were most likely natural fluctuations caused by environmental factors (Table S3). STZ-induced T1D altered the production of SCFA and lactic acid T1D was associated with a significant decrease in caecal propionate (P,.5) and butyrate (P,.5) and a significant increase in caecal acetate (P,.5) and lactate levels (P,.5), compared with healthy controls (Fig. 8). No differences in formate were exhibited between the groups (Fig. 8). Alistipes, Ruminococcus and Ruminococcaceae incertae sedis were reduced (P,.5; Fig. 6) in the T1D group when compared with healthy controls. Data highlighting the intestinal microbiota changed 5 weeks following T1D induction, compared with healthy controls, corresponding to microbiota populations from the caecal content of the rats after they had been killed. Thus, week 5 data were graphed separately from the other time points as variations between the microbiota of faecal and caecal content may skew results. The proportions of Actinobacteria and Proteobacteria remained higher compared with healthy controls (P,.5; Fig. 7a). The abundance of Deferribacteres decreased (P,.5; Fig. 7a) in the T1D group, compared with healthy controls. Similar to week 4, the proportions of Bacteroidaceae, Bifidobacteriaceae and Alcaligenaceae were increased (P,.5; Fig. 7b), while Ruminococcaceae and Peptococcaceae were reduced (P,.5; Fig. 7b) in the T1D group, compared with healthy controls. The proportions of Rikenellaceae and Peptostreptococcaceae were also reduced (P,.5; Fig. 7b) in the T1D group, compared with healthy controls, while Erysipelotrichaceae was higher (P,.5; Fig. 7b), in the T1D group, compared with healthy controls. At the genus level, DISCUSSION This study provides a comprehensive account of the impact STZ-induced T1D on the intestinal microbiota composition, diversity and microbial fermentation metabolite production over time. The antimicrobial effect of STZ has previously been described (Vavra et al., 1959), however, very little is understood of the antimicrobial impact a single intraperitoneal injection of STZ could have on intestinal microbiota composition. In man, STZ has a circulating half-life of only 15 min, following intravenous infusion (Schein et al., 1973) or 3 4 min following intravenous bolus injection (Adolphe et al., 1975). Approximately 7 % of 14 C-labelled-STZ administered intravenously to rats in single doses of 7 mg STZ kg 21 was recovered in the urine over the first 6 h, thus indicating rapid excretion (Karunanayake et al., 1976). It is therefore unlikely that the changes to microbiota composition found in this study were caused by the antimicrobial activity of STZ and were most likely a result of T1D onset and progression. Further, the antimicrobial activity of STZ was assessed on a separate group of rats that received the STZ injection but did not develop T1D. Their failure to develop T1D excluded them from the study as they did not meet 188 Microbiology 161

8 Impact of STZ-induced T1D on microbiota composition (a) (b) (c) Relative abundance versus controls (%) Actinobacteria Proteobacteria Deferribacteres Relative abundance versus controls (%) Bacteroidaceae Rikenellaceae Bifidobacteriaceae Erysipelotrichaceae Peptostreptococcaceae Ruminococcaceae Alcaligenaceae Peptococcaceae Relative abundance versus controls (%) Parasutterella Bacteroides Alistipes Bifidobacterium Peptostreptococcaceae Incertae Sedis Phascolarctobacterium Ruminococcus Ruminococcaceae Incertae Sedis Mucispirillum Fig. 7. Phylum (a), family (b) and genus (c) level distributions of the microbial communities either significantly increased or decreased in the caecal content of T1D rats, compared with healthy controls (n51 per group) at week 5. The non-parametric Mann Whitney test was used to estimate the relationship between the groups. Statistical significance was accepted at P,.5. the requirements of the T1D group; however, DNA was isolated from faecal pellets collected from these rats (n52) at each time point and caecal content at week 5. The STZ toxin did not appear to have a strong antimicrobial effect SCFA/lactate/formate (umol g 1 ) *** ** Healthy T1D Formate Acetate Propionate Butyrate Lactate Total SCFA Fig. 8. Caecal content SCFA, lactate and formate concentrations in T1D and healthy control rats (n51 per group). Unpaired Student s t-test was used to compare the levels of caecal acetate, propionate, butyrate, lactate and formate between the groups. Values are means±sem, represented by vertical bars. Statistical significance was accepted at P,.5. *P,.5, **P,.1, ***P,.1. *** *** * on these rats and reflected changes to the microbiota composition did not correlate with the changes seen in the T1D group over time. Despite the low sample size, these rats provided a valuable dataset on the antimicrobial activity of STZ. The data revealed that STZ-induced T1D increased the Bacteroidetes : Firmicutes ratio, as previously demonstrated in various T1D models (de Goffau et al., 213; Giongo et al., 211; Murri et al., 213). Initially, pre-t1d induction, no differences in the Bacteroidetes : Firmicutes ratio was observed between the groups. In contrast, the intestinal relative proportions of Actinobacteria and Proteobacteria were significantly increased at weeks 4 and 5 following T1D induction, compared with healthy controls. Interestingly, the proportions of Proteobacteria are often negatively associated with inflammatory bowel conditions (Sartor & Mazmanian, 212). The Bacteroidetes : Firmicutes ratio has frequently been associated with the obese phenotype, with a greater capacity to extract energy from the diet (Murphy et al., 21). In addition, work carried out recently by Liou et al. (213) demonstrated conserved shifts in the intestinal microbiota composition resulting from weight loss following Roux-en-Y gastric bypass surgery (Liou et al., 213). While T1D rats in this study did experience dramatic weight loss following diabetes induction, due to the high loss of calories derived from sugar in the urine and the consequential breakdown of fat 189

9 E. Patterson and others cells for energy, they also experienced hyperphagia in an attempt to maintain body weight. Changes in the microbiota coincide with the loss of body weight in the T1D rats following 1 week of diabetes development, suggesting that the changes to body weight may have affected microbiota composition. However, since weight loss is a symptom of untreated T1D, both factors should be considered in this scenario as insulin therapy was not administered. Sequencing technologies have highlighted a positive association between a diverse microbiota and health. Decreases in the number and abundance distribution of distinct intestinal microbes has been linked with various intestinal diseases (Manichanh et al., 26; Sartor, 28; Turnbaugh et al., 29) and, in particular, T1D (Brown et al., 211; de Goffau et al., 213; Giongo et al., 211; Knip et al., 211). Microbial diversity was significantly decreased just 1 week post-stz-induced T1D and failed to recover during disease progression. Principal co-ordinate analyses revealed a temporal decrease in diversity in T1D rats, compared with healthy controls. As disease progressed over the 5 weeks, the individual microbiota populations of T1D rats became less diverse, compared with healthy controls and failed to cluster together distinctly, suggesting vast alterations in the intestinal microbiota composition between T1D rats. a- Diversity metrics demonstrated a decrease in bacterial diversity following T1D onset and progression, compared with healthy controls. Interestingly, the phylogenetic diversity and observed species a-diversity metrics demonstrated a reduction in diversity between weeks and 1 compared with week 4, in the healthy group with age as a possible contributing factor towards this. Age-related decreases in intestinal microbial diversity have previously been described (O Toole & Claesson, 21). It is likely that the intestinal environmental conditions created following T1D onset decreased microbial diversity, creating an opportunity for members of the phyla Actinobacteria and Proteobacteria to thrive. These data correlated with previous observations (Giongo et al., 211), that T1D was associated with decreased abundances of Ruminococcaceae and Lachnospiraceae and increased abundances of Bacteroidaceae, compared with healthy controls at the later stages of T1D development. However, in contrast to this study, which found Porphyromonadaceae significantly more abundant in healthy control children, the data generated in this study revealed that the proportions of Porphyromonadaceae were higher in T1D rats, 1 and 4 weeks after T1D induction and lower at week 2, compared with healthy controls. This highlights temporal variations to intestinal microbiota composition in response to T1D progression. The relative proportions of Bifidobacteriaceae, Lactobacillaceae and Clostridiaceae were all increased in T1D rats at the later stages of T1D progression. The intestinal surface barrier is one of the most important components of the innate immune system (Vaarala et al., 28), whereby T1D compromises intestinal integrity (Carratù et al., 1999; Kuitunen et al., 22; Sapone et al., 26). Abnormalities of the intestinal barrier, the so-called leaky gut, expose the intestinal immune system to antigens in the setting of T1D (Vaarala et al., 28). An impaired intestinal microbiota composition in children pre-diagnosed with autoimmune diabetes has previously been associated with altered microbial fermentation metabolite production (Brown et al., 211). Butyrate producers such as Eubacterium, Fusobacterium, Anaerostipes and Roseburia were higher in the faeces of a control group of healthy children. Lactic acid producers such as Lactobacillus, Lactococcus, Bifidobacterium and Streptococcus were higher in the faeces of children pre-diagnosed with autoimmune diabetes (Brown et al., 211). The fate of lactate is crucial in determining intestinal health as conversion to butyrate results in mucin synthesis (Barcelo et al., 2; Burger-van Paassen et al., 29; Finnie et al., 1995; Shimotoyodome et al., 2) and tighter junctions (Peng et al., 27, 29), while conversion to other SCFA, such as propionate and acetate does not induce mucin synthesis (Brown et al., 211). Mucin is a glycoprotein made by the host that maintains the integrity of intestinal epithelium (Brown et al., 211). In addition, butyrate contributes to colonic health through its anti-inflammatory properties (Hamer et al., 28; Louis & Flint, 29; Pryde et al., 22) and decreases bacterial transport across metabolically stressed epithelia (Louis & Flint, 29), thus preventing the development of the so-called leaky gut. The data in this study revealed increases in the abundances of lactic acid producing bacteria such as Bifidobacterium and Lactobacillus in T1D rats, as were the concentrations of lactate and acetate, while butyrate was decreased in the caecum of T1D rats, compared with healthy controls. Furthermore, the proportions of Bacteroides were higher 2 and 5 weeks after T1D onset, compared with healthy controls. Bacteroides have recently been implicated in both diabetic animal and human studies (Brown et al., 211; Brugman et al., 26; de Goffau et al., 213; Giongo et al., 211; Roesch et al., 29). Such studies have highlighted an association between Bacteroides and enhanced intestinal bacterial translocation, resulting in b-cell autoimmunity, associated with T1D (de Goffau et al., 213). Bifidobacteria have previously been associated with an inhibition of bacterial translocation (Duffy, 2; Romond et al., 28; Wang et al., 24) and it has recently been hypothesized (de Goffau et al., 213) that bifidobacteria may inhibit the translocation and growth of Bacteroides as they compete for space and/or adherence (Stecher & Hardt, 28) and nutrients (Gibson et al., 1996). Furthermore, bifidobacteria enhance the intestinal epithelial barrier function (Liévin et al., 2) by increasing the thickness of the mucous layer (Kleessen & Blaut, 25; Kleessen et al., 23). Thus, increased proportions of Bifidobacterium in the T1D group, as seen in this study at the later stages of diabetes progression may enhance intestinal epithelial barrier function. This study highlighted temporal variations in the intestinal microbiota of T1D rats. Although these data did not provide any data on functional changes related to the 19 Microbiology 161

10 Impact of STZ-induced T1D on microbiota composition observed bacterial diversity, the results provide an extensive account of the impact STZ-induced T1D onset and progression has on the intestinal microbiota composition, diversity and microbial metabolite production in the host. Moreover, the data clarified that the changes observed in the intestinal microbiota of T1D rats resulted from disease development only and did not have any causative role in the onset of diabetes. ACKNOWLEDGEMENTS We acknowledge the technical assistance of Fiona Crispie, Teagasc Food Research Centre, Biosciences Department, Moorepark, Fermoy, Co. Cork, Ireland and Colette Manley, Biosciences Institute, UCC. E. P. was supported by funding from the Teagasc Walsh Fellowship Scheme and the work was supported by the Science Foundation of Ireland funded Centre for Science, Engineering and Technology, the Alimentary Pharmabiotic Centre, CSET grant 7/CE/B1368. The authors declare that there are no conflicts of interest. REFERENCES Adolphe, A. B., Glasofer, E. D., Troetel, W. M., Ziegenfuss, J., Stambaugh, J. E., Weiss, A. J. & Manthei, R. W. (1975). Fate of streptozotocin (NSC-85998)in patients with advanced cancer. Cancer Chemother Rep 59, Altschul, S. F., Madden, T. L., Schäffer, A. A., Zhang, J., Zhang, Z., Miller, W. & Lipman, D. J. (1997). Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res 25, Atkinson, M. A. & Chervonsky, A. (212). Does the gut microbiota have a role in type 1 diabetes? Early evidence from humans and animal models of the disease. Diabetologia 55, Barcelo, A., Claustre, J., Moro, F., Chayvialle, J. A., Cuber, J. C. & Plaisancié, P. (2). Mucin secretion is modulated by luminal factors in the isolated vascularly perfused rat colon. Gut 46, Bellavia, M., Tomasello, G., Romeo, M., Damiani, P., Lo Monte, A. I., Lozio, L., Campanella, C., Marino Gammazza, A., Rappa, F. & other authors (213). Gut microbiota imbalance and chaperoning system malfunction are central to ulcerative colitis pathogenesis and can be counteracted with specifically designed probiotics: a working hypothesis. Med Microbiol Immunol 22, Boerner, B. P. & Sarvetnick, N. E. (211). Type 1 diabetes: role of intestinal microbiome in humans and mice. Ann N Y Acad Sci 1243, Brown, C. T., Davis-Richardson, A. G., Giongo, A., Gano, K. A., Crabb, D. B., Mukherjee, N., Casella, G., Drew, J. C., Ilonen, J. & other authors (211). Gut microbiome metagenomics analysis suggests a functional model for the development of autoimmunity for type 1 diabetes. PLoS ONE 6, e Brugman, S., Klatter, F. A., Visser, J. T., Wildeboer-Veloo, A. C., Harmsen, H. J., Rozing, J. & Bos, N. A. (26). Antibiotic treatment partially protects against type 1 diabetes in the Bio-Breeding diabetesprone rat. Is the gut flora involved in the development of type 1 diabetes? Diabetologia 49, Burger-van Paassen, N., Vincent, A., Puiman, P. J., van der Sluis, M., Bouma, J., Boehm, G., van Goudoever, J. B., van Seuningen, I. & Renes, I. B. (29). The regulation of intestinal mucin MUC2 expression by short-chain fatty acids: implications for epithelial protection. Biochem J 42, Calcinaro, F., Dionisi, S., Marinaro, M., Candeloro, P., Bonato, V., Marzotti, S., Corneli, R. B., Ferretti, E., Gulino, A. & other authors (25). Oral probiotic administration induces interleukin-1 production and prevents spontaneous autoimmune diabetes in the non-obese diabetic mouse. Diabetologia 48, Caporaso, J. G., Kuczynski, J., Stombaugh, J., Bittinger, K., Bushman, F. D., Costello, E. K., Fierer, N., Peña, A. G., Goodrich, J. K. & other authors (21). QIIME allows analysis of high-throughput community sequencing data. Nat Methods 7, Cardwell, C. R., Stene, L. C., Joner, G., Cinek, O., Svensson, J., Goldacre, M. J., Parslow, R. C., Pozzilli, P., Brigis, G. & other authors (28). Caesarean section is associated with an increased risk of childhood-onset type 1 diabetes mellitus: a meta-analysis of observational studies. Diabetologia 51, Carratù, R., Secondulfo, M., de Magistris, L., Iafusco, D., Urio, A., Carbone, M. G., Pontoni, G., Cartenì, M. & Prisco, F. (1999). Altered intestinal permeability to mannitol in diabetes mellitus type I. J Pediatr Gastroenterol Nutr 28, Chen, V. B., Davis, I. W. & Richardson, D. C. (29). KING (Kinemage, Next Generation): a versatile interactive molecular and scientific visualization program. Protein Sci 18, de Goffau, M. C., Luopajärvi, K., Knip, M., Ilonen, J., Ruohtula, T., Härkönen, T., Orivuori, L., Hakala, S., Welling, G. W. & other authors (213). Fecal microbiota composition differs between children with b-cell autoimmunity and those without. Diabetes 62, Dominguez-Bello, M. G., Costello, E. K., Contreras, M., Magris, M., Hidalgo, G., Fierer, N. & Knight, R. (21). Delivery mode shapes the acquisition and structure of the initial microbiota across multiple body habitats in newborns. Proc Natl Acad Sci U S A 17, Duffy, L. C. (2). Interactions mediating bacterial translocation in the immature intestine. J Nutr 13 (Suppl), 432S 436S. Ehehalt, S., Dietz, K., Willasch, A. M., Neu, A. & Baden-Württemberg Diabetes Incidence Registry (DIARY) Group (21). Epidemiological perspectives on type 1 diabetes in childhood and adolescence in Germany: 2 years of the Baden-Württemberg Diabetes Incidence Registry (DIARY). Diabetes Care 33, Finnie, I. A., Dwarakanath, A. D., Taylor, B. A. & Rhodes, J. M. (1995). Colonic mucin synthesis is increased by sodium butyrate. Gut 36, Gibson, G. R., Willems, A., Reading, S. & Collins, M. D. (1996). Fermentation of non-digestible oligosaccharides by human colonic bacteria. Proc Nutr Soc 55, Giongo, A., Gano, K. A., Crabb, D. B., Mukherjee, N., Novelo, L. L., Casella, G., Drew, J. C., Ilonen, J., Knip, M. & other authors (211). Toward defining the autoimmune microbiome for type 1 diabetes. ISME J 5, Greenblum, S., Turnbaugh, P. J. & Borenstein, E. (212). Metagenomic systems biology of the human gut microbiome reveals topological shifts associated with obesity and inflammatory bowel disease. Proc Natl Acad Sci U S A 19, Haas, B. J., Gevers, D., Earl, A. M., Feldgarden, M., Ward, D. V., Giannoukos, G., Ciulla, D., Tabbaa, D., Highlander, S. K. & other authors (211). Chimeric 16S rrna sequence formation and detection in Sanger and 454-pyrosequenced PCR amplicons. Genome Res 21, Hamer, H. M., Jonkers, D., Venema, K., Vanhoutvin, S., Troost, F. J. & Brummer, R. J. (28). Review article: the role of butyrate on colonic function. Aliment Pharmacol Ther 27, Huson, D. H., Auch, A. F., Qi, J. & Schuster, S. C. (27). MEGAN analysis of metagenomic data. Genome Res 17,

11 E. Patterson and others Karunanayake, E. H., Hearse, D. J. & Mellows, G. (1976). Streptozotocin: its excretion and metabolism in the rat. Diabetologia 12, King, C. & Sarvetnick, N. (211). The incidence of type-1 diabetes in NOD mice is modulated by restricted flora not germ-free conditions. PLoS ONE 6, e1749. Kleessen, B. & Blaut, M. (25). Modulation of gut mucosal biofilms. Br J Nutr 93 (Suppl. 1), S35 S4. Kleessen, B., Hartmann, L. & Blaut, M. (23). Fructans in the diet cause alterations of intestinal mucosal architecture, released mucins and mucosa-associated bifidobacteria in gnotobiotic rats. Br J Nutr 89, Klimesova, K., Kverka, M., Zakostelska, Z., Hudcovic, T., Hrncir, T., Stepankova, R., Rossmann, P., Ridl, J., Kostovcik, M. & other authors (213). Altered gut microbiota promotes colitis-associated cancer in IL-1 receptor-associated kinase M-deficient mice. Inflamm Bowel Dis 19, Knip, M., Virtanen, S. M., Becker, D., Dupré, J., Krischer, J. P., Åkerblom, H. K. & TRIGR Study Group (211). Early feeding and risk of type 1 diabetes: experiences from the Trial to Reduce Insulindependent diabetes mellitus in the Genetically at Risk (TRIGR). Am J Clin Nutr 94 (Suppl.), 1814S 182S. Kruskal, W. H. & Wallis, W. A. (1952). Use of ranks in one-criterion variance analysis. J Am Stat Assoc 47, Kuitunen, M., Saukkonen, T., Ilonen, J., Akerblom, H. K. & Savilahti, E. (22). Intestinal permeability to mannitol and lactulose in children with type 1 diabetes with the HLA-DQB1*2 allele. Autoimmunity 35, Lenzen, S. (28). The mechanisms of alloxan- and streptozotocininduced diabetes. Diabetologia 51, Ley, R. E., Bäckhed, F., Turnbaugh, P., Lozupone, C. A., Knight, R. D. & Gordon, J. I. (25). Obesity alters gut microbial ecology. Proc Natl Acad Sci U S A 12, Ley, R. E., Turnbaugh, P. J., Klein, S. & Gordon, J. I. (26). Microbial ecology: human gut microbes associated with obesity. Nature 444, Liévin, V., Peiffer, I., Hudault, S., Rochat, F., Brassart, D., Neeser, J. R. & Servin, A. L. (2). Bifidobacterium strains from resident infant human gastrointestinal microflora exert antimicrobial activity. Gut 47, Liou, A. P., Paziuk, M., Luevano, J. M., Jr, Machineni, S., Turnbaugh, P. J. & Kaplan, L. M. (213). Conserved shifts in the gut microbiota due to gastric bypass reduce host weight and adiposity. Sci Transl Med 5, 178ra41. Louis, P. & Flint, H. J. (29). Diversity, metabolism and microbial ecology of butyrate-producing bacteria from the human large intestine. FEMS Microbiol Lett 294, 1 8. Manichanh, C., Rigottier-Gois, L., Bonnaud, E., Gloux, K., Pelletier, E., Frangeul, L., Nalin, R., Jarrin, C., Chardon, P. & other authors (26). Reduced diversity of faecal microbiota in Crohn s disease revealed by a metagenomic approach. Gut 55, Murphy, E. F., Cotter, P. D., Healy, S., Marques, T. M., O Sullivan, O., Fouhy, F., Clarke, S. F., O Toole, P. W., Quigley, E. M. & other authors (21). Composition and energy harvesting capacity of the gut microbiota: relationship to diet, obesity and time in mouse models. Gut 59, Murri, M., Leiva, I., Gomez-Zumaquero, J. M., Tinahones, F. J., Cardona, F., Soriguer, F. & Queipo-Ortuño, M. I. (213). Gut microbiota in children with type 1 diabetes differs from that in healthy children: a case-control study. BMC Med 11, 46. Noble, J. A. & Erlich, H. A. (212). Genetics of type 1 diabetes. Cold Spring Harb Perspect Med 2, a7732. Notkins, A. L. & Lernmark, A. (21). Autoimmune type 1 diabetes: resolved and unresolved issues. J Clin Invest 18, O Toole, P. W. & Claesson, M. J. (21). Gut microbiota: changes throughout the lifespan from infancy to elderly. Int Dairy J 2, Patterson, C. C., Dahlquist, G., Soltész, G., Green, A. & EURODIAB ACE Study Group. Europe and Diabetes (21). Is childhood-onset type I diabetes a wealth-related disease? An ecological analysis of European incidence rates. Diabetologia 44 (Suppl. 3), B9 B16. Peng, L., He, Z., Chen, W., Holzman, I. R. & Lin, J. (27). Effects of butyrate on intestinal barrier function in a Caco-2 cell monolayer model of intestinal barrier. Pediatr Res 61, Peng, L., Li, Z. R., Green, R. S., Holzman, I. R. & Lin, J. (29). Butyrate enhances the intestinal barrier by facilitating tight junction assembly via activation of AMP-activated protein kinase in Caco-2 cell monolayers. J Nutr 139, Price, M. N., Dehal, P. S. & Arkin, A. P. (21). FastTree 2 approximately maximum-likelihood trees for large alignments. PLoS ONE 5, e949. Pruesse, E., Quast, C., Knittel, K., Fuchs, B. M., Ludwig, W., Peplies, J. & Glöckner, F. O. (27). SILVA: a comprehensive online resource for quality checked and aligned ribosomal RNA sequence data compatible with ARB. Nucleic Acids Res 35, Pryde, S. E., Duncan, S. H., Hold, G. L., Stewart, C. S. & Flint, H. J. (22). The microbiology of butyrate formation in the human colon. FEMS Microbiol Lett 217, Rea, M. C., Dobson, A., O Sullivan, O., Crispie, F., Fouhy, F., Cotter, P. D., Shanahan, F., Kiely, B., Hill, C. & Ross, R. P. (211). Effect of broad- and narrow-spectrum antimicrobials on Clostridium difficile and microbial diversity in a model of the distal colon. Proc Natl Acad Sci U S A 18 (Suppl. 1), Roesch, L. F., Lorca, G. L., Casella, G., Giongo, A., Naranjo, A., Pionzio, A. M., Li, N., Mai, V., Wasserfall, C. H. & other authors (29). Culture-independent identification of gut bacteria correlated with the onset of diabetes in a rat model. ISME J 3, Romond, M. B., Colavizza, M., Mullié, C., Kalach, N., Kremp, O., Mielcarek, C. & Izard, D. (28). Does the intestinal bifidobacterial colonisation affect bacterial translocation? Anaerobe 14, Sapone, A., de Magistris, L., Pietzak, M., Clemente, M. G., Tripathi, A., Cucca, F., Lampis, R., Kryszak, D., Cartenì, M. & other authors (26). Zonulin upregulation is associated with increased gut permeability in subjects with type 1 diabetes and their relatives. Diabetes 55, Sartor, R. B. (28). Microbial influences in inflammatory bowel diseases. Gastroenterology 134, Sartor, R. B. & Mazmanian, S. K. (212). Intestinal microbes in inflammatory bowel diseases. Am J Gastroenterol Suppl 1, Schein, P., Kahn, R., Gorden, P., Wells, S. & Devita, V. T. (1973). Streptozotocin for malignant insulinomas and carcinoid tumor. Report of eight cases and review of the literature. Arch Intern Med 132, Shimotoyodome, A., Meguro, S., Hase, T., Tokimitsu, I. & Sakata, T. (2). Short chain fatty acids but not lactate or succinate stimulate mucus release in the rat colon. Comp Biochem Physiol A Mol Integr Physiol 125, Stecher, B. & Hardt, W. D. (28). The role of microbiota in infectious disease. Trends Microbiol 16, Turnbaugh, P. J., Ley, R. E., Mahowald, M. A., Magrini, V., Mardis, E. R. & Gordon, J. I. (26). An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 444, Microbiology 161

The Gut Microbiota: Evidence For Gut Microbes as Contributors to Weight Gain

The Gut Microbiota: Evidence For Gut Microbes as Contributors to Weight Gain The Gut Microbiota: Evidence For Gut Microbes as Contributors to Weight Gain Michael T. Bailey, Ph.D. Center for Microbial Pathogenesis The Research Institute, Nationwide Children s Hospital Department

More information

Gut Microbiota and IBD. Vahedi. H M.D Associate Professor of Medicine DDRI

Gut Microbiota and IBD. Vahedi. H M.D Associate Professor of Medicine DDRI Gut Microbiota and IBD Vahedi. H M.D Associate Professor of Medicine DDRI 1393.3.1 2 GUT MICROBIOTA 100 Trillion Microbes - 10 times more than cells in our body Collective weight of about 1kg in human

More information

Slide 1. Slide 2 Learning outcomes. Slide 3. Year 1 MBChB Lecture 15 Introduction to the Gut Microbiota. The importance of microbiota

Slide 1. Slide 2 Learning outcomes. Slide 3. Year 1 MBChB Lecture 15 Introduction to the Gut Microbiota. The importance of microbiota Slide 1 Year 1 MBChB Lecture 15 Introduction to the Gut Microbiota Professor Barry Campbell Gastroenterology Research Unit Cellular & Molecular Physiology, Institute of Translational Medicine bjcampbl@liv.ac.uk

More information

Supplementary Figures and Tables

Supplementary Figures and Tables Supplementary Figures and Tables Supplementary Figure 1. Intestinal epithelial MyD88 deletion decreases fat mass under HFD. (a) Final fat mass expressed as a percentage of final body weight (n=25). (b)

More information

The Gut Microbiome: 101 Justin Carlson University of Minnesota

The Gut Microbiome: 101 Justin Carlson University of Minnesota The Gut Microbiome: 101 Justin Carlson University of Minnesota Where are we now? 360 B.C. 2003 Human Gut Microbes Associated With Obesity Ley et al., Nature. 2006. Consumer Driven Science For Better of

More information

PREBIOTIC MECHANISMS OF ACTION

PREBIOTIC MECHANISMS OF ACTION PREBIOTIC MECHANISMS OF ACTION Seema Hooda, Kelly S. Swanson, George C. Fahey, Jr. Department t of Animal Sciences Division of Nutritional Sciences University of Illinois at Urbana-Champaign Institute

More information

Gut Reaction. Mary ET Boyle, Ph. D. Department of Cognitive Science UCSD

Gut Reaction. Mary ET Boyle, Ph. D. Department of Cognitive Science UCSD Gut Reaction Mary ET Boyle, Ph. D. Department of Cognitive Science UCSD Ley, R. et al (2005) PNAS vol. 102 no. 31 Bacterial diversity in the distal gut (ceca) of C57BL6 mice. (A) Phylogenetic tree of

More information

Microbiome GI Disorders

Microbiome GI Disorders Microbiome GI Disorders Prof. Ram Dickman Neurogastroenterology Unit Rabin Medical Center Israel 1 Key Points Our gut microbiota Were to find them? Symbiosis or Why do we need them? Dysbiosis or when things

More information

Figure S1, SDC Additional measures of microbial diversity during perioperative period In addition to the Shannon diversity index of Figure 1,

Figure S1, SDC Additional measures of microbial diversity during perioperative period In addition to the Shannon diversity index of Figure 1, Figure S1, SDC Additional measures of microbial diversity during perioperative period In addition to the Shannon diversity index of Figure 1, additional measures of diversity are shown: Figure S2, SDC

More information

GUT MICROBIOME WHAT IS IT? WHY IS IT IMPORTANT FOR HUMAN HEALTH?

GUT MICROBIOME WHAT IS IT? WHY IS IT IMPORTANT FOR HUMAN HEALTH? GUT MICROBIOME WHAT IS IT? WHY IS IT IMPORTANT FOR HUMAN HEALTH? Corrie Whisner, PhD School of Nutrition and Health Promotion Arizona State University Center for Research on Ingredient Safety Annual Meeting

More information

HOW THE MICROBIOME AFFECTS OUR HEALTH

HOW THE MICROBIOME AFFECTS OUR HEALTH HOW THE MICROBIOME AFFECTS OUR HEALTH THE INTESTINAL BARRIER AND INTESTINAL PERMEABILITY Intestinal Barrier: a functional body Defense from translocation of dietary antigens, bacteria or bacterial endotoxins

More information

Gut microbiota and health in elderly subjects a role for probiotics? Paul W. O Toole

Gut microbiota and health in elderly subjects a role for probiotics? Paul W. O Toole Gut microbiota and health in elderly subjects a role for probiotics? Paul W. O Toole School of Microbiology, Univ. College Cork, Ireland Alimentary Pharmabiotic Centre, Univ. College Cork, Ireland http://apc.ucc.ie

More information

Microbiome 101: Sequencing, Nomenclature, and Methodology

Microbiome 101: Sequencing, Nomenclature, and Methodology Microbiome 101: Sequencing, Nomenclature, and Methodology Ian Carroll, PhD Assistant Professor Division of Gastroenterology and Hepatology UNC Chapel Hill Background Microbiota: an ecological community

More information

Diet, microbiota and the immune system: A gut feeling about type 1 diabetes. Dr. Eliana Mariño Monash University Melbourne, Australia

Diet, microbiota and the immune system: A gut feeling about type 1 diabetes. Dr. Eliana Mariño Monash University Melbourne, Australia Diet, microbiota and the immune system: A gut feeling about type 1 diabetes Dr. Eliana Mariño Monash University Melbourne, Australia Diet, gut microbiota and Western lifestyle diseases Asthma Fatty liver

More information

Role of the Gut Microbiota in Autoimmunity

Role of the Gut Microbiota in Autoimmunity Role of the Gut Microbiota in Autoimmunity Pavan Bhargava, MD - Neuroimmunology Fellow Division of Neuroimmunology and Neurological Infections Johns Hopkins University, Baltimore, MD. May, 2015 None Disclosures

More information

The enteric microbiota: Implications for IBD. Eugene B. Chang, M.D. University of Chicago

The enteric microbiota: Implications for IBD. Eugene B. Chang, M.D. University of Chicago The enteric microbiota: Implications for IBD Eugene B. Chang, M.D. University of Chicago On a per cell basis, humans are mostly prokaryote 100 90 80 70 60 50 40 30 20 10 0 EuK ProK The microbial flora

More information

LIFESTYLE-ASSOCIATED ALTERATIONS OF INTESTINAL

LIFESTYLE-ASSOCIATED ALTERATIONS OF INTESTINAL LIFESTYLE-ASSOCIATED ALTERATIONS OF INTESTINAL MICROBIOTA AND THEIR POTENTIAL ROLE IN ETIOLOGY OF IBD: A METAGENOMIC ANALYSIS Stephan J. Ott, University Hospital (UKSH), Campus Kiel Institute for Clinical

More information

The role of gut microbiome in IBS

The role of gut microbiome in IBS The role of gut microbiome in IBS Chung Owyang, MD H. Marvin Pollard Professor of Internal Medicine Professor of Molecular and Integrative Physiology Chief, Division of Gastroenterology Director, Pollard

More information

Hygiene Hypothesis: 10 years later. Christina Ciaccio MD, MSc Assistant Professor The University of Chicago

Hygiene Hypothesis: 10 years later. Christina Ciaccio MD, MSc Assistant Professor The University of Chicago Hygiene Hypothesis: 10 years later Christina Ciaccio MD, MSc Assistant Professor The University of Chicago none Disclosures Definitions Microbe: Microscopic organism Microbiota: Microbial community Definition

More information

6/24/2014. How do you study microbial communities? Outnumbers Cells of the Body 10:1 Outnumber Human Genes 100:1. Michael T. Bailey, Ph.D.

6/24/2014. How do you study microbial communities? Outnumbers Cells of the Body 10:1 Outnumber Human Genes 100:1. Michael T. Bailey, Ph.D. Interactions between Diet and the Intestinal Microbiota: Implications for Obesity The Body is Colonized by an Enormous Array of Bacteria Outnumbers Cells of the Body 10:1 Outnumber Human Genes 100:1 Michael

More information

INTESTINAL MICROBIOTA EXAMPLES OF INDIVIDUAL ANALYSES

INTESTINAL MICROBIOTA EXAMPLES OF INDIVIDUAL ANALYSES EXAMPLES OF INDIVIDUAL ANALYSES INTESTINAL MICROBIOTA Microbiota in the animal or human intestine has evolved together with the host. Consequently, the gastrointestinal tract could be considered a metacommunity,

More information

The role of nutrition in optimum gastrointestinal health

The role of nutrition in optimum gastrointestinal health The role of nutrition in optimum gastrointestinal health Kelly A. Tappenden, Ph.D., R.D., FASPEN Kraft Foods Human Nutrition Endowed Professor University Distinguished Teacher-Scholar University of Illinois

More information

The impact of the microbiome on brain and cognitive development

The impact of the microbiome on brain and cognitive development The Gut-Brain Axis The impact of the microbiome on brain and cognitive development Diane Stadler, PhD, RD Oregon Health & Sciences University, Portland, Oregon Lao-American Nutrition Institute With acknowledgements

More information

New Insights on the Structure of the Human Gut Microbiota. Chaysavanh Manichanh, PhD Vall d Hebron Research Institute Barcelona

New Insights on the Structure of the Human Gut Microbiota. Chaysavanh Manichanh, PhD Vall d Hebron Research Institute Barcelona New Insights on the Structure of the Human Gut Microbiota Chaysavanh Manichanh, PhD Vall d Hebron Research Institute Barcelona Sessio Societat Catalana Malalties Infecciosas i Microbiologia March 20th,

More information

Examining the effects of pre and probiotics on gut microbiota during the ageing process

Examining the effects of pre and probiotics on gut microbiota during the ageing process Session: Reviewing key ingredients shaping nutrition for healthy ageing Tuesday 22 nd November 2016 Examining the effects of pre and probiotics on gut microbiota during the ageing process Louise R Wilson

More information

ISSN: (Print) (Online) Journal homepage:

ISSN: (Print) (Online) Journal homepage: Gut Microbes ISSN: 1949-0976 (Print) 1949-0984 (Online) Journal homepage: http://www.tandfonline.com/loi/kgmi20 The structures of the colonic mucosa-associated and luminal microbial communities are distinct

More information

Microbiome in You: Optimizing Gut Bacteria for Better IBD Management

Microbiome in You: Optimizing Gut Bacteria for Better IBD Management Microbiome in You: Optimizing Gut Bacteria for Better IBD Management KT Park, M.D., M.S. Assistant Professor Co-Director, Stanford Children s Inflammatory Bowel Disease Center Stanford University School

More information

HUMAN GUT MICROBIOTA

HUMAN GUT MICROBIOTA HUMAN GUT MICROBIOTA Patrizia Brigidi Department of Pharmaceutical Sciences, University of Bologna, Italy patrizia.brigididi@unibo.it The Gut-Liver axis: a bidirectional relation in health and disease

More information

Microbiome and Asthma

Microbiome and Asthma 제 12 차천식연구회 COPD 연구회공동심포지엄 Microbiome and Asthma 한양대학교병원호흡기알레르기내과 김상헌 Disclosure 내용 1 Lung Microbiome 2 Lung Microbiome and Asthma 3 Gut Microbiome and Asthma Microbiome and Microbiota human microbiome

More information

Going With Your Gut: The Microbiome and You

Going With Your Gut: The Microbiome and You Going With Your Gut: The Microbiome and You Robert T. Schooley, MD Professor of Medicine University of California San Diego San Diego, California Learning Objectives After attending this presentation,

More information

SUPPLEMENTARY INFORMATION

SUPPLEMENTARY INFORMATION doi:10.1038/nature12198 1. Supplementary results 1.1. Associations between gut microbiota, glucose control and medication Women with T2D who used metformin had increased levels of Enterobacteriaceae (i.e.

More information

The role of intestinal microbiota in metabolic disease-a novel therapeutic target.

The role of intestinal microbiota in metabolic disease-a novel therapeutic target. Michael Connolly Department of Food Biosciences, The University of Reading The role of intestinal microbiota in metabolic disease-a novel therapeutic target. University of Reading 2008 www.reading.ac.uk

More information

Exploration of the microbiota in inflammatory diseases. Matthew Stoll MD Research Computing Day September 13, 2012

Exploration of the microbiota in inflammatory diseases. Matthew Stoll MD Research Computing Day September 13, 2012 Exploration of the microbiota in inflammatory diseases Matthew Stoll MD Research Computing Day September 13, 2012 We re surrounded by bugs Human body contains 100 trillion microbes Out-number human cells

More information

traits and fasdng TMAO concentradons..6

traits and fasdng TMAO concentradons..6 FIGURE S1: Variability of gut microbiota composidon in Metsim samples 2 FIGURE S2: AssociaDon of bacterial diversity and richness measures with traits.3 FIGURE S3: AssociaDons of OTUs with fasdng blood

More information

Dysbiosis & Inflammation

Dysbiosis & Inflammation MASTERING THE MICROBIOME: Dysbiosis & Inflammation 2017 Tom Fabian, PhD It is reasonable to propose that the composition of the microbiome and its activities are involved in most, if not all, of the biological

More information

Ali Keshavarzian MD Rush University Medical Center, Chicago, IL

Ali Keshavarzian MD Rush University Medical Center, Chicago, IL Ali Keshavarzian MD Rush University Medical Center, Chicago, IL Ulcerative colitis Crohn s disease Optimize Quality of Life Induce remission [treat flare up] Maintain remission [avoid flare up] Prevent

More information

Analysis of the effect of probiotics on shaping human gut microbiota

Analysis of the effect of probiotics on shaping human gut microbiota Analysis of the effect of probiotics on shaping human gut microbiota Masahira HATTORI Center for Omics and Bioinformatics, The University of Tokyo http://www.cb.k.u-tokyo.ac.jp/hattorilab

More information

The Intestinal Microbiota and the Developing Immune System

The Intestinal Microbiota and the Developing Immune System The Intestinal Microbiota and the Developing Immune System 4 Feb 2016 The Intestinal Microbiota 10 fold more bacterial cells than human cells 100-1000 fold more bacterial genes than human genes Why does

More information

Diet-microbiome-health interactions in older people

Diet-microbiome-health interactions in older people Diet-microbiome-health interactions in older people Paul W. O Toole Prof. Microbial Genomics School of Microbiology, Univ. College Cork, Ireland APC Microbiome Institute, Univ. College Cork, Ireland http://apc.ucc.ie

More information

EFFECTS OF ANTIBIOTIC PROPHYLAXIS ON THE PERFORMANCE AND GUT MICROBIOTA OF GROWING BROILER CHICKS

EFFECTS OF ANTIBIOTIC PROPHYLAXIS ON THE PERFORMANCE AND GUT MICROBIOTA OF GROWING BROILER CHICKS EFFECTS OF ANTIBIOTIC PROPHYLAXIS ON THE PERFORMANCE AND GUT MICROBIOTA OF GROWING BROILER CHICKS Alexandra Tonks Supervisors: Dr Caroline Rymer, Prof Martin Woodward School of Agriculture, University

More information

The number of microorganisms residing in our intestines is 10 times the number of our somatic and germ cells.

The number of microorganisms residing in our intestines is 10 times the number of our somatic and germ cells. The number of microorganisms residing in our intestines is 10 times the number of our somatic and germ cells. The number of microorganisms residing in our intestines is 10 times the number of our somatic

More information

Understanding probiotics and health

Understanding probiotics and health Understanding probiotics and health Gemma Laws MSc Student Microbiology and Immunology Department The gut microbiota The name given to the total microbial population living in our intestine Bacteria, fungi,

More information

Supplementary Figures. Supplementary Figure 1. Treatment schematic of SIV infection and ARV and PP therapies.

Supplementary Figures. Supplementary Figure 1. Treatment schematic of SIV infection and ARV and PP therapies. Supplementary Figures Supplementary Figure 1. Treatment schematic of SIV infection and ARV and PP therapies. Supplementary Figure 2. SIV replication and CD4 + T cell count. (A) Log SIVmac239 copies/ml

More information

Gut Lung Axis Implication of the Gut Microbiota beyond its niche

Gut Lung Axis Implication of the Gut Microbiota beyond its niche Gut Lung Axis Implication of the Gut Microbiota beyond its niche Reema Subramanian PhD Candidate (4 th year) Supervisor: Prof. Margaret Ip Department of Microbiology, CUHK Joint Graduate Student Seminar

More information

PREBIOTICS, THE INTESTINAL MICROBIOME AND BONE HEALTH

PREBIOTICS, THE INTESTINAL MICROBIOME AND BONE HEALTH PREBIOTICS, THE INTESTINAL MICROBIOME AND BONE HEALTH Corrie Whisner, PhD School of Nutrition and Health Promotion Arizona State University June 7, 2017 OVERVIEW 1. Osteoporosis 1. Prevalence 2. Prevention

More information

Dietary Fiber and its Influence on Gut Health

Dietary Fiber and its Influence on Gut Health Dietary Fiber and its Influence on Gut Health Dietary Fiber and its Influence on Gut Health It is well known that dietary fiber plays a significant role in preventing non-communicable diseases such as

More information

Gut Microbiomes of Malawian Twin Pairs Discordant for Kwashiorkor

Gut Microbiomes of Malawian Twin Pairs Discordant for Kwashiorkor Gut Microbiomes of Malawian Twin Pairs Discordant for Kwashiorkor Michelle I. Smith et al. Science 339, 548 (2013) Dept Meeting, 28 May 2013, M. UMEZAKI ABSTRACT. Kwashiorkor, an enigmatic form of severe

More information

SCFA in gut health. Kristin Verbeke. On behalf of the Prebiotic Task Force of ILSI Europe

SCFA in gut health. Kristin Verbeke. On behalf of the Prebiotic Task Force of ILSI Europe SCFA in gut health Kristin Verbeke Translational Research in Gastrointestinal Disorders KU Leuven On behalf of the Prebiotic Task Force of ILSI Europe Acetic acid Major anions in the large intestine Propionic

More information

Intestinal Microbiota in Health and Disease

Intestinal Microbiota in Health and Disease Intestinal Microbiota in Health and Disease February 27, 2015 Master s Course in Gastroenterology Prof. Kathy McCoy 1 Overview Overview of Gut Microbiota Microbiota in Health Microbiota in Disease 2 Gut

More information

Diet-Microbiota Interactions and The Elderly

Diet-Microbiota Interactions and The Elderly DEPARTMENT OF AGTTC GATCGATTTGTC G ACCCAG C T A AGGATAGAGTGAT GA UNIVERSITY COLLEGE CORK Diet-Microbiota Interactions and The Elderly Ian Jeffery Dept. Microbiology, Univ. College Cork, Ireland Alimentary

More information

Dynamics of the human gut microbiome in inflammatory bowel disease

Dynamics of the human gut microbiome in inflammatory bowel disease In the format provided by the authors and unedited. SUPPLEMENTARY INFORMATION VOLUME: 2 ARTICLE NUMBER: 174 Dynamics of the human gut microbiome in inflammatory bowel disease Jonas Halfvarson, Colin J.

More information

Fecal Microbiota Transplantation for Severe sepsis and Diarrhea : a Case Report

Fecal Microbiota Transplantation for Severe sepsis and Diarrhea : a Case Report Fecal Microbiota Transplantation for Severe sepsis and Diarrhea : a Case Report Qiurong Li Institute of General Surgery, Jinling Hospital Nanjing Univeristy Gut Microbiota 100 trillion cells 10-fold of

More information

INTRODUCING YOUR GUT BACTERIA

INTRODUCING YOUR GUT BACTERIA INTRODUCING YOUR GUT BACTERIA Microflora Intestinal flora 1.5 kg We would die with 5 years of birth if we did not have them as we would not develop a proper immune system 1000 species and 5000 strains

More information

Stool Testing for the Microbiome - Ready for Primetime?

Stool Testing for the Microbiome - Ready for Primetime? Stool Testing for the Microbiome - Ready for Primetime? Gillian M. Barlow, PhD Project Scientist, Medically Associated Science and Technology (MAST) Program Cedars-Sinai Medical Center Take Charge of

More information

Time of day and eating behaviors are associated with the composition and function of the human gastrointestinal microbiota

Time of day and eating behaviors are associated with the composition and function of the human gastrointestinal microbiota Time of day and eating behaviors are associated with the composition and function of the human gastrointestinal microbiota Jennifer L Kaczmarek, 1 Salma MA Musaad, 2 and Hannah D Holscher 1 3 1 Division

More information

Are microbes the missing piece of the gut comfort puzzle?

Are microbes the missing piece of the gut comfort puzzle? Priority Research Programme Foods for improving gut function and comfort Are microbes the missing piece of the gut comfort puzzle? Wayne Young Senior Scientist, AgResearch Host institution Foods for gut

More information

Microbiome, allergy and inflammatory diseases

Microbiome, allergy and inflammatory diseases Microbiome, allergy and inflammatory diseases 1. NCDs & inflammation 2. Microbiome &GI inflammatory pathologies 3. Microbiome & autoimmunity 4. Microbiome & neurophaties 5. Microbiome & NAFLD 6. Microbiome

More information

The A, B, C s of Bowel Flora

The A, B, C s of Bowel Flora The A, B, C s of Bowel Flora Cynthia L. Sears, M.D. Divisions of Infectious Diseases, Gastroenterology & Tumor Immunology Departments of Medicine, Oncology & Molecular Microbiology Sidney Kimmel Comprehensive

More information

The vital role of the microbiome in human health

The vital role of the microbiome in human health The vital role of the microbiome in human health abandoning hygiene is not the way to a healthy microbiome Colin Hill APC Microbiome Institute University College Cork @colinhillucc Mixed messages? We live

More information

Alexander Shikhman MD, PhD Institute for Specialized Medicine July 20, 2013

Alexander Shikhman MD, PhD Institute for Specialized Medicine July 20, 2013 Alexander Shikhman MD, PhD Institute for Specialized Medicine July 20, 2013 SPONDYLOARTHROPATHIES The spondyloarthropathy family consists of the following entities: Ankylosing spondylitis Undifferentiated

More information

DO SWEETENERS AFFECT THE GUT MICROBIOME?

DO SWEETENERS AFFECT THE GUT MICROBIOME? DO SWEETENERS AFFECT THE GUT MICROBIOME? What does the science and evidence tell us? Alexandra Lobach, M.Sc., Ph.D. Manager, Toxicology, Chemistry & Regulatory Affairs Food & Nutrition Health, Environmental

More information

Microbiome and liver diseases

Microbiome and liver diseases Klinik und Poliklinik für Innere Medizin I Microbiome and liver diseases Bernd Schnabl, M.D. Department of Medicine I have no financial relationship relevant to my presentation AND my presentation does

More information

Health Benefits of Prebiotic Dietary Fiber

Health Benefits of Prebiotic Dietary Fiber Health Benefits of Prebiotic Dietary Fiber JENNIFER ERICKSON, PhD, RD Objectives Provide some background on dietary fiber To define the term "prebiotic dietary fiber" To discuss potential health effects

More information

Microbial Adaptations of the Microbiome. Damian R. Plichta, PhD Director of Bioinformatics

Microbial Adaptations of the Microbiome. Damian R. Plichta, PhD Director of Bioinformatics Microbial Adaptations of the Microbiome Damian R. Plichta, PhD Director of Bioinformatics Tailored shotgun metagenomics Microbiome model for biomarker discovery microbiome incoming species conditional

More information

Microbiome as Predictor of Benefit and Toxicity in Cancer Immunotherapy

Microbiome as Predictor of Benefit and Toxicity in Cancer Immunotherapy Microbiome as Predictor of Benefit and Toxicity in Cancer Immunotherapy Giuliana Magri, Ph.D Optimizing Immunotherapy New Approaches, Biomarkers, Sequences and Combinations PRBB Auditorium, Barcelona October

More information

Benakis et al. Supplementary Figure 1

Benakis et al. Supplementary Figure 1 Benakis et al. Supplementary Figure a flora Naive C7BL/ d AC weeks d S rrna sequencing Antibiotic in drinking water Stool pellet collection riginal seeder flora flora Naive C7BL/ d AC weeks d S rrna sequencing

More information

Gut Microbiome Essentials

Gut Microbiome Essentials CORE COMPONENTS I: Gut Microbiome Essentials 2016 Tom Fabian, PhD Module Outline 1. Microbiome overview: getting a sense of the microbiome, research, what we know 2. Bacteria: features, functions, communities

More information

Diet, Microbiome and Health Cindy D. Davis

Diet, Microbiome and Health Cindy D. Davis Diet, Microbiome and Health Cindy D. Davis davisci@mail.nih.gov OFFICE OF DIETARY SUPPLEMENTS 1 Outline 1.What is the microbiome? 2.How does it vary over the lifespan? 3.What is the evidence that diet

More information

Consistent and Reproducible Production of a Microbiota-based Drug for Recurrent C. difficile

Consistent and Reproducible Production of a Microbiota-based Drug for Recurrent C. difficile Consistent and Reproducible Production of a Microbiota-based Drug for Recurrent C. difficile Infection: Application of a Novel Diagnostic for Dysbiosis Courtney Jones, BS Rebiotix Inc. Roseville, MN USA

More information

Gut microbiota, metabolic syndrome, obesity and the nutrient sensor pathways

Gut microbiota, metabolic syndrome, obesity and the nutrient sensor pathways Gut microbiota, metabolic syndrome, obesity and the nutrient sensor pathways Department of Gastroenterology, Endocrinology & Metabolism Medical University Innsbruck Herbert Tilg Nothing to disclose Fig.

More information

Clinically proven to quickly relieve symptoms of common gastrointestinal disorders. TERRAGASTRO - Good health starts in the gut

Clinically proven to quickly relieve symptoms of common gastrointestinal disorders. TERRAGASTRO - Good health starts in the gut Clinically proven to quickly relieve symptoms of common gastrointestinal disorders GASTROINTESTINAL DISEASE Referred to as gastrointestinal diseases, they are common disorders which affect the esophagus,

More information

Structural modulation of the gut microbiota and the relationship with body weight: compared evaluation of liraglutide and saxagliptin treatment

Structural modulation of the gut microbiota and the relationship with body weight: compared evaluation of liraglutide and saxagliptin treatment Structural modulation of the gut microbiota and the relationship with body weight: compared evaluation of liraglutide and saxagliptin treatment Lin Wang, Peicheng Li, Zhaosheng Tang, Xinfeng Yan, Bo Feng

More information

Our microbiome: The role of vital gut bacteria, diet, nutrition and obesity

Our microbiome: The role of vital gut bacteria, diet, nutrition and obesity Our microbiome: The role of vital gut bacteria, diet, nutrition and obesity Prof Kevin Whelan Professor of Dietetics King s College London @ProfWhelan #BSG2017 Speaker Declarations This presenter has the

More information

Gut Microbiome Metagenomics Analysis Suggests a Functional Model for the Development of Autoimmunity for Type 1 Diabetes

Gut Microbiome Metagenomics Analysis Suggests a Functional Model for the Development of Autoimmunity for Type 1 Diabetes Gut Microbiome Metagenomics Analysis Suggests a Functional Model for the Development of Autoimmunity for Type 1 Diabetes Christopher T. Brown 1, Austin G. Davis-Richardson 1, Adriana Giongo 1, Kelsey A.

More information

Paul Cotter Teagasc Food Research Centre & APC

Paul Cotter Teagasc Food Research Centre & APC http://apc.ucc.ie Research into the relationship between digestive bacteria, nutrition and health Paul Cotter Teagasc Food Research Centre & APC paul.cotter@teagasc.ie Our microbes - Some impressive facts

More information

The ISME Journal (2010), 1 10 & 2010 International Society for Microbial Ecology All rights reserved /10 $32.00

The ISME Journal (2010), 1 10 & 2010 International Society for Microbial Ecology All rights reserved /10 $32.00 (2010), 1 10 & 2010 International Society for Microbial Ecology All rights reserved 1751-7362/10 $32.00 www.nature.com/ismej ORIGINAL ARTICLE Toward defining the autoimmune microbiome for type 1 diabetes

More information

Microbe-Host Interactions in Inflammatory Bowel Diseases. Hera Vlamakis Oct 3, 2018

Microbe-Host Interactions in Inflammatory Bowel Diseases. Hera Vlamakis Oct 3, 2018 Microbe-Host Interactions in Inflammatory Bowel Diseases Hera Vlamakis Oct 3, 2018 Most of the bacteria in your body are in your gut HEALTH BENEFITS Breakdown of polysaccharides Synthesis of vitamins Colonization

More information

7/30/2018. Nutricia North America 1. Learning Objectives

7/30/2018. Nutricia North America 1. Learning Objectives Probiotics, Prebiotics and the Role of the Infant Intestinal Microbiota in Health and Allergic Disease Kelly Tappenden, Ph.D, R.D. Kelly Tappenden, Ph.D, R.D. Professor and Department Head Department of

More information

general meeting 1 20 October 2016

general meeting 1 20 October 2016 general meeting 1 20 October 2016 introductions today s topics the human microbiome about the study the human microbiome the human microbiome human microbiota: the microorganisms that live within and on

More information

Probiotics in the ICU. Who could benefit? Nadia J van Rensburg RD(SA) Groote Schuur Hospital, Cape Town

Probiotics in the ICU. Who could benefit? Nadia J van Rensburg RD(SA) Groote Schuur Hospital, Cape Town Probiotics in the ICU. Who could benefit? Nadia J van Rensburg RD(SA) Groote Schuur Hospital, Cape Town Outline Introduction: a brief overview Probiotics: Current guidelines Reviews and Meta-analyses IBD

More information

Research Article Antitumor Ability of Berberine Accompanied by Modulation of Gut Microbiome in Sarcoma-180 Tumor-bearing Mice

Research Article Antitumor Ability of Berberine Accompanied by Modulation of Gut Microbiome in Sarcoma-180 Tumor-bearing Mice OPEN ACCESS International Journal of Pharmacology ISSN 1811-7775 DOI: 1.3923/ijp.218.46.47 Research Article Antitumor Ability of Berberine Accompanied by Modulation of Gut Microbiome in Sarcoma-18 Tumor-bearing

More information

Issues at Hand. Inflammatory Bowel Disease Paradigm. Diet changes the fecal microbiome. Experience with diet in IBD

Issues at Hand. Inflammatory Bowel Disease Paradigm. Diet changes the fecal microbiome. Experience with diet in IBD Diet s Role in IBD David Suskind M.D. Professor of Pediatrics Director of Clinical Gastroenterology Division of Gastroenterology University of Washington Seattle Children s Hospital Issues at Hand Inflammatory

More information

9/18/2018. The Physiological Roles of the Intestinal Microbiota. Learning Objectives

9/18/2018. The Physiological Roles of the Intestinal Microbiota. Learning Objectives The Physiological Roles of the Intestinal Microbiota Kelly A. Tappenden, Ph.D., R.D., FASPEN Professor and Head, Kinesiology and Nutrition University Distinguished Teacher-Scholar University of Illinois

More information

ROLE OF THE GUT BACTERIA

ROLE OF THE GUT BACTERIA ROLE OF THE GUT BACTERIA Our Good Bacteria In a perfect world, we would all have a proper ratio of good bacteria And what could this proper ratio do for us? The knowledge of the connections between our

More information

SIMPOSIO Il microbiota intestinale e la sua modulazione nelle patologie dell asse intestino cervello. Microbiota e IBS.

SIMPOSIO Il microbiota intestinale e la sua modulazione nelle patologie dell asse intestino cervello. Microbiota e IBS. SIMPOSIO Il microbiota intestinale e la sua modulazione nelle patologie dell asse intestino cervello Microbiota e IBS Cesare Cremon Policlinico S. Orsola Malpighi Azienda Ospedaliero - Universitaria di

More information

Manuscript Title: Responses in ileal and cecal bacteria to low and high amylose/amylopectin ratio diets in growing pigs

Manuscript Title: Responses in ileal and cecal bacteria to low and high amylose/amylopectin ratio diets in growing pigs Journal name: Applied Microbiology and Biotechnology Manuscript Title: Responses in ileal and cecal bacteria to low and high amylose/amylopectin ratio diets in growing pigs The names of the authors: Yu-heng

More information

Mark Manary MD. International Symposium on Understanding Moderate Malnutrition in Children for Effective Interventions

Mark Manary MD. International Symposium on Understanding Moderate Malnutrition in Children for Effective Interventions Possible role of the microbiome in the development of acute malnutrition and implications for food-based strategies to prevent and treat acute malnutrition International Symposium on Understanding Moderate

More information

Impaired gut health: the root of systemic disorders in cattle

Impaired gut health: the root of systemic disorders in cattle Impaired gut health: the root of systemic disorders in cattle Qendrim Zebeli An inside outside approach to dairy cow health University of Veterinary Medicine, Vienna Gut and disease 2 12.2.219 1 Diet for

More information

Poultry The unique probiotic

Poultry The unique probiotic Poultry The unique probiotic Probiotics Probiotics have been defined as live microbial feed supplements which beneficially affect the host animal by improving its intestinal microbial balance. Achieving

More information

Abstract. Integrated Immunology Clinic Articles ã

Abstract. Integrated Immunology Clinic Articles ã Integrated Immunology Clinic Articles ã Assessment of the relevance of intestinal Zonulin test for inflammatory conditions in an integrated clinical setting. El-Doueik Abigail 1, El-Doueik Haytham 2,3

More information

Exosomes as a. Novel Therapeutic Approach to Gastrointestinal Diseases Rebecca Murray APRN, FNP, CDE

Exosomes as a. Novel Therapeutic Approach to Gastrointestinal Diseases Rebecca Murray APRN, FNP, CDE Exosomes as a Novel Therapeutic Approach to Gastrointestinal Diseases Rebecca Murray APRN, FNP, CDE Endocrine Nurse Practitioner Institute for Hormonal Balance Orlando, FL Medical Director Ward-Murray

More information

Breastfeeding and the Microbiome

Breastfeeding and the Microbiome Breastfeeding and the Microbiome JENNY WALTERS MPH, IBCLC Objectives At the conclusion of this session, participants will be able to: Identify ways the microbiota is passed from mother to baby Identify

More information

MICROBIOM AND OBESITY HEINZ GYAKY 2018 BUDAPEST

MICROBIOM AND OBESITY HEINZ GYAKY 2018 BUDAPEST MICROBIOM AND OBESITY HEINZ GYAKY 2018 BUDAPEST HUMAN MICROBIOM 10 Billion bacterias are building a 1,5 2 kg heavy human microbiom It is located mainly in the human gut There is a intestinal controlled

More information

WEBINAR Microbial Metabolism Associated with Health. 12 April 2018; CET

WEBINAR Microbial Metabolism Associated with Health. 12 April 2018; CET WEBINAR Microbial Metabolism Associated with Health 12 April 2018; 15.00-16.30 CET PROGRAMME Brief Introduction of Both Organisations and Scientific Background Dr Bettina Schelkle (ILSI Europe, BE) Dr

More information

Disclosures. Outline. Nothing to disclose. Dysbiosis and the gut barrier. Endotoxemia and the liver. Impact of products of bacterial metabolism

Disclosures. Outline. Nothing to disclose. Dysbiosis and the gut barrier. Endotoxemia and the liver. Impact of products of bacterial metabolism Disclosures Nothing to disclose Outline Dysbiosis and the gut barrier Endotoxemia and the liver Impact of products of bacterial metabolism 1 Dysbiosis in obesity Obesity: Dysbiosis, shown in multiple settings

More information

The Gut Microbiome: What Do We Know?

The Gut Microbiome: What Do We Know? REVIEW The Gut Microbiome: What Do We Know? Francisco Guarner, M.D., Ph.D. Our body is a planet populated by myriad microorganisms. Such companions are not casual bystanders or potential invaders when

More information

Module Outline. 1. Microbiome overview: getting a sense of the microbiome, research, what we know

Module Outline. 1. Microbiome overview: getting a sense of the microbiome, research, what we know Module Outline 1. Microbiome overview: getting a sense of the microbiome, research, what we know 2. Bacteria: features, functions, communities & taxonomy 3. Other microbes: archaea, fungi, viruses, parasites

More information

Stable Isotope Probing of gut bacteria RNA. Wayne Young. Identifying gut bacteria that can use sialic acid using an RNA-SIP approach

Stable Isotope Probing of gut bacteria RNA. Wayne Young. Identifying gut bacteria that can use sialic acid using an RNA-SIP approach Stable Isotope Probing of gut bacteria RNA Identifying gut bacteria that can use sialic acid using an RNA-SIP approach Wayne Young Food Nutrition & Health Team Food & Bio-based Products Group AgResearch

More information

Probiotic action and health and well-being of children. Seppo Salminen Functional Foods Forum Finland

Probiotic action and health and well-being of children. Seppo Salminen Functional Foods Forum Finland Probiotic action and health and well-being of children Seppo Salminen Functional Foods Forum Finland DEFINITION OF A PROBIOTIC Probiotic:...a living microbial preparation, which beneficially influences

More information

VITAMINS, MINERALS AND THE GUT

VITAMINS, MINERALS AND THE GUT VITAMINS, MINERALS AND THE GUT Nutrients Looking at individual nutrients that are involved with gut health can be misleading This is not about taking individual nutrients It supports more a whole food

More information